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Mucosal surfaces are the primary sites for the transmission of infectious agents including viruses, so effective vaccines
generally should induce mucosal immunity. Furthermore, noninvasive delivery is desirable because of the ease of application, the
high degree of patient compliance, and the improved safety for patients and clinicians due to the elimination of needles.
Unfortunately, most of the conventional vaccines are parenterally administered and result in systemic rather than mucosal
immunity. Here we present the first report of mucosal immunity by noninvasive DNA immunization in a target species. As an
approach to induce mucosal immunity against bovine herpesvirus-1, cows were immunized intravaginally with suppositories
containing plasmid coding for glycoprotein D. Serum IgG, as well as IgA both in the serum and in the nasal fluids, were detected,
which supports the contention of a common mucosal immune system. This level of immunity was of sufficient magnitude to
minimize weight loss and significantly reduce the duration of virus shedding after intranasal viral challenge, which demonstrates
the efficacy of suppository-based administration of DNA vaccines to target species. As this is a very practical method of delivery,
it has great potential to be applied as vaccine or therapy in a variety of species. © 2001 Academic PressINTRODUCTION
Many infectious agents, including a large number of
viruses, are transmitted through mucosal surfaces. Un-
fortunately, most of the conventional vaccines are paren-
terally administered and result in systemic rather than
mucosal immunity. In contrast, mucosal immunization
induces mucosal as well as systemic immunity (Ogra et
al., 1994). DNA vaccines, also referred to as the “third
generation of vaccines,” bear several advantages over
conventional vaccines, such as safety, stability, and effi-
cacy in the presence of maternal antibodies (Donnelly et
al., 1997). However, although it has been shown that DNA
immunization of pigs, horses, and cattle by gene gun at
mucosal sites primes the development of mucosal im-
munity (Macklin et al., 1998; Lunn et al., 1999; Loehr et al.,
2000), no active mucosal immune response was actually
elicited. Furthermore, the use of the gene gun is not
practical yet, so it is desirable to develop other, prefer-
ably noninvasive, delivery methods because of the ease
of application, the high degree of patient compliance,
and the improved safety for patients and clinicians.
Noninvasive DNA immunization applied to mucosal
surfaces should combine ease of administration and
efficacy as a mucosal vaccine. DNA vaccines have been
1 Published as VIDO Journal Series Number 291.
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327shown to induce a primary IgA response in mice when
administered intranasally (Fynan et al., 1993; Kuklin et al.,
1997; Asakura et al., 1997; Lundholm et al., 1999; Klavin-
skis et al., 1999) or intravaginally (Wang et al., 1997).
However, only in a few instances has protection been
described after mucosal noninvasive DNA immunization
of mice and chickens (Fynan et al., 1993; Daheshia et al.,
1998; Chen et al., 1998). Successful noninvasive DNA
immunization of large animals or humans has not been
reported and yet could open avenues for a new area of
mucosal immunization.
Bovine herpesvirus-1 (BHV-1) is an economically im-
portant pathogen in cattle. Clinical signs include rhino-
tracheitis, conjunctivitis, vulvovaginitis, balanoposthitis,
and abortions, some of which may lead to secondary
bacterial infections (Yates, 1982). We have previously
demonstrated that the major glycoproteins of BHV-1, gB,
gC, and gD can induce systemic immunity and protection
in cattle when administered as a subunit vaccine (Babiuk
et al., 1987; van Drunen Littel-van den Hurk et al., 1990).
The protection levels were shown to directly correlate to
IgG in the nasal secretions, which essentially is a tran-
sudate from the serum (van Drunen Littel-van den Hurk
et al., 1993). Plasmids encoding gB or gD have also been
shown to induce systemic immune responses when ad-
ministered by gene gun to cattle (Braun et al., 1999;
Loehr et al., 2000). However, since mucosal surfaces
constitute the primary sites of infection for BHV-1, muco-
sal immune responses are desirable and probably es-
sential for the induction of long-term immunity.
In this study, the potential of the genital tract as a site
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328 LOEHR ET AL.for mucosal DNA vaccination was investigated. Cattle
were immunized with suppositories containing plasmid
coding for gD and subsequently challenged with BHV-1.
This noninvasive method of immunization resulted in
protective systemic and distal mucosal immune re-
sponses, which makes this the first report on mucosal
immunity elicited by noninvasive DNA immunization in a
target species.
RESULTS
Induction of systemic and distal mucosal immune
responses by DNA immunization
To assess the potential of the genital tract as an
induction site for mucosal immunity, plasmids encoding
gD and tgD were formulated in suppositories. To deter-
mine that the formulation into suppository base did not
affect the physical state of the DNA, the plasmids were
recovered from the suppositories and visualized by aga-
rose gel electrophoresis. This showed that the plasmids
were unaltered by the formulation and retained the same
degree of supercoil (Fig. 1). The plasmid-containing sup-
positories were administered intravaginally to cattle. Gly-
coprotein D-specific antibody titers were determined
both in serum and in nasal fluids (Fig. 2). The IgA titers in
the sera (P , 0.01) and the nasal secretions (P , 0.05),
as well as the serum IgG titers (P , 0.05) of the vacci-
nated group, were significantly higher than the titers of
the control group. In contrast, the IgG titers in the nasal
fluids were low in both the vaccinated and the control
group.
Induction of anamnestic immune responses after
BHV-1 challenge
FIG. 1. Plasmids expressing BHV-1 gD and tgD prior to formulation
nto suppository base (lane 1), after reheating at 39°C (lane 2), and after
eheating and ethanol precipitation (lane 3). The plasmids were run on
1% agarose gel. Molecular weight markers (lane M) (kB) are shown
n the right margin.After challenge, the difference between the vaccinated
group and the control group became even more obvious.Regardless of the source or isotype of the antibody, the
titers of the control group never equaled those of the
vaccinated group (Fig. 3). The serum IgA titers in the
vaccinated group remained relatively stable during the
entire period postchallenge and although the IgA titers of
the control group increased slightly, they remained sig-
nificantly lower than those of the vaccinated group (P ,
0.01) (Fig. 3a). Although after challenge the nasal IgA
levels increased steadily in both groups, the titers of the
vaccinated group were significantly higher than those of
the control group at the time of challenge (P , 0.05) and
afterward (P , 0.01) (Fig. 3b). To confirm that the antigen-
specific IgA detected in the nasal fluid was locally pro-
duced by pIgA1 plasma cells, an enzyme-linked immu-
nosorbent assay (ELISA) was performed with antibodies
specific for bovine secretory IgA (sIgA). In contrast to the
sera, the nasal fluids of the vaccinated group indeed
contained gD-specific sIgA in significantly (P , 0.01)
higher amounts than the fluids of the control group (Figs.
3c and 3d). Furthermore, size exclusion chromatography
confirmed the presence of dimeric IgA in the nasal fluids
(data not shown). The control group did not show IgG
titers greater than 10 in the serum or nasal fluids until
day 10 and 13 postchallenge, respectively, but the ani-
mals immunized with plasmid-containing suppositories
showed a significant antibody titer increase as early as
day 6 in serum (P , 0.001) (Fig. 3e) and nasal secretions
(P , 0.05) (Fig. 3f).
Protection from BHV-1 challenge
To assess the biological relevance of the gD-specific
antibodies, virus neutralization titers were determined in
FIG. 2. Humoral immune responses prior to BHV-1 challenge. Cattle
were immunized with gD encoding plasmid in suppositories (s) or left
untreated (c). Glycoprotein D-specific IgG and IgA titers were deter-
mined in serum and nasal fluids prevaccination and postvaccination
(prior to BHV-1 challenge). ELISA titers are expressed as the highest
dilution resulting in a reading of two standard deviations above the
value of a negative control sample. Significant differences between the
groups are indicated as *P , 0.05, **P , 0.01.
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329SUPPOSITORY-MEDIATED DNA IMMUNIZATION OF CATTLEthe sera and nasal fluids. Neutralizing antibodies devel-
oped earlier and reached significantly higher levels in
the vaccinated group than in the control group (P , 0.01),
ith titers greater than 64 as early as day 8 postchal-
FIG. 3. Humoral immune responses after BHV-1 challenge. Cattle we
(c). Glycoprotein D-specific IgA (a, b), sIgA (c, d), and IgG (e, f) titers w
expressed as the reciprocal of the highest dilution resulting in a readi
Significant differences between the groups are indicated as *P , 0.05enge in the sera (Fig. 4a), so the kinetics of the neutral-
zing antibody response was similar to that of the IgG
(
besponse. Furthermore, elevated neutralizing antibody
evels were present in the nasal fluids of the vaccinated
roup from day 8 postchallenge and overall were signif-
cantly higher than those of the control group (P , 0.05)
unized with gD encoding plasmid in suppositories (s) or left untreated
termined in serum (a, c, e) and nasal fluids (b, d, f). ELISA titers are
o standard deviations above the value of a negative control sample.
0.01, ***P , 0.001.re imm
ere deFig. 4b). One of the objective indicators for the well-
eing of an animal and the level of protection achieved is
330 LOEHR ET AL.the amount of weight loss measured postchallenge. Al-
though all animals lost some weight (Fig. 5a), the ani-
mals in the vaccinated group maintained their weight
better than the control group. This difference in weight
loss between the vaccinated group and the control group
was obvious between days 2 and 6 postchallenge (Fig.
5a). As a further objective measurement of protection,
the amount of virus recovered from the nasal secretions
was measured over a 2-week period after challenge.
Nasal virus shedding was observed from day 2 onward
in both groups. The maximum level of virus shedding in
the control group occurred on day 6 postchallenge, and
shedding was still observed on day 10. In contrast, the
nasal shedding in the vaccinated group rapidly de-
creased from day 8 onward and overall was significantly
lower than in the control group (P , 0.01) (Fig. 5b). The
challenge was very severe, so elevated temperatures
and clinical disease were observed in all animals, with-
out a significant difference between the vaccinated and
control groups.
DISCUSSION
FIG. 4. Effect of immunization on virus neutralization titers in the
serum (a) and nasal fluids (b). Prior to challenge, cattle were immunized
with gD encoding plasmid in suppositories (s) or left untreated (c). Virus
neutralization titers are expressed as a 50% endpoint using 100 PFU
BHV-1. Significant differences between the groups are indicated as
*P , 0.05, **P , 0.01.In this study mucosal immunity was induced in a target
species by noninvasive administration of suppositoriescontaining a DNA vaccine to the bovine genital tract. This
simple vaccination regime generated systemic and mu-
cosal IgA and conferred a degree of protection from
subsequent challenge infection.
Among several studies in mice using mucosal sur-
faces as immunization sites (reviewed in McCluskie et
al., 1998), some report that noninvasive DNA immuniza-
tion can induce an IgA response in serum as well as at
the inductive and distal mucosal site (Kuklin et al., 1997;
Asakura et al., 1997; Daheshia et al., 1998; Lundholm et
al., 1999). In some studies the vaginal route was used to
induce mucosal immunity. For example, after intravaginal
immunization with plasmid coding for HIV-1 envelope
proteins, neutralizing antibodies were present in the vag-
inal fluid in mice (Wang et al., 1997). In contrast, intra-
vaginal immunization with cholera toxin barely led to an
IgA response in mice, although by oral, gastric, and
rectal administration IgA was induced in oral, intestinal,
and genital tract secretions (Haneberg et al., 1994). Sim-
ilarly, intravaginal immunization with a recombinant ad-
enovirus expressing gB of HSV-1 induced no or little IgA
in the serum or vaginal tract, in contrast to effective
intranasal administration (Gallichan and Rosenthal,
1995). The induction of IgA after intravaginal DNA immu-
nization reported here suggests that the responsiveness
of the genital tract to immunizations with DNA and pro-
tein is different and thus should be further evaluated.
FIG. 5. Effect of immunization on weights and virus shedding. (a)
Average cumulative weight change. (b) Nasal shedding of BHV-1. Sig-
nificant differences between the groups are indicated as **P , 0.01.
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331SUPPOSITORY-MEDIATED DNA IMMUNIZATION OF CATTLEThere are only a few reports on noninvasive DNA
immunization of animals other than rodents. Chickens
were partially protected from challenge with influenza
virus after intratracheal DNA immunization (Fynan et al.,
993). Intravaginal instillation of HIV-1 DNA constructs in
wo chimpanzees resulted in antibody titers of 1:25 and
:400 (Bagarazzi et al., 1997). Furthermore, oral applica-
ion of DNA coding for BHV-1 gC was effective as a
rimary vaccination in combination with intradermal
NA immunization (R. Rankin et al., unpublished obser-
ations) and oral immunization of fetal lambs with plas-
id coding for BHV-1 gD resulted in specific antibody
iters and T-cell stimulation (Gerdts et al., 2000). How-
ver, none of these studies have described the induction
f systemic or mucosal IgA and there is no other report
n noninvasive DNA immunization of any other relevant
eterinary species (Babiuk et al., 2000).
In the present trial, intravaginal DNA immunization of
attle resulted in the induction of serum IgG as well as
igh levels of serum IgA. Furthermore, the nasal fluids
ontained sIgA, which supports the contention of a com-
on mucosal immune system. Although an anamnestic
esponse has been observed after DNA immunization by
ene gun with plasmid coding for BHV-1 gD or gB in
attle (Braun et al., 1999; Loehr et al., 2000), in those
ases DNA immunization failed to initiate a primary IgA
esponse. Primary IgA also was not reported in the other
wo studies on gene gun immunizations in large animals,
hen DNA was administered both to skin and to muco-
al surfaces in pigs and horses (Macklin et al., 1998;
unn et al., 1999). Thus, this represents the first report on
he induction of mucosal IgA by DNA immunization of
arget species.
The lack of knowledge concerning the mechanism of
NA uptake via the mucosa and the fact that the sup-
ositories are based on noncharged hard fats leaves
mple room for improvement. In various studies it has
een shown that cationic liposomes in particular im-
rove the immune response to DNA immunization in
ice, not only when applied intramuscularly (Ishii et al.,
997; Gregoriadis et al., 1997), but also to the respiratory
pithelium (Felgner et al., 1995; Klavinskis et al., 1997,
999; Xin et al., 1998; Sha et al., 1999). For example,
ntranasal delivery of DNA coding for HA along with
iposomes or bioadhesive polymers increased the im-
une response 5–10 times (Sha et al., 1999). It is as-
umed that not only the slower release of DNA from
iposomes for up to 2 weeks after intramuscular injection
Singh et al., 2000), but also the lipid component itself,
ontribute to the increase in immune response (Barron et
l., 1999). By modifying the fat composition of the sup-
ository base to include charged lipids, the efficacy of
he suppositories as a delivery vehicle may be further
nhanced.The convenience and efficacy of DNA uptake in cattle
y the mucosal route shows great potential for several “reventive as well as therapeutic applications. In addi-
ion to generating active mucosal immunity through DNA
mmunization against a variety of infectious agents, in-
ravaginal immunization with DNA vaccines could be
pplied to the induction of IgA in milk for passive pre-
ention of neonatal infections, as well as prevention of
nfections occurring in the birth canal. Indeed, pregnant
oats, intranasally immunized with a plasmid coding for
he 15-kDa surface sporozoite protein of Cryptospo-
idium parvum, transferred immunity to their offspring,
onferring protection against C. parvum infection (Sa-
odira et al., 1999). Furthermore, formulating nucleic ac-
ds in suppositories may provide a means to combat a
road spectrum of illnesses based on nucleic acid ther-
pies such as polynucleotide immunostimulants, anti-
ense drugs, or nucleotide-analog antiviral agents.
In conclusion, our results show that noninvasive DNA
mmunization via the bovine genital tract represents an
pproach that results in the induction of systemic and
ucosal IgA. As this is a very practical method, it has
reat potential for application to vaccination or other
herapies in a variety of species including humans. To
urther optimize suppository-mediated DNA immuniza-
ion, the immune responses and their induction mecha-
ism in comparison to noninvasive protein immunization
s under further investigation.
MATERIALS AND METHODS
ells and viruses
Bovine viral diarrhea virus free Madin–Darby bovine
idney (MDBK) cells were cultured in minimal essential
edium (MEM; Gibco-BRL, Grand Island, NY), supple-
ented with 10% fetal bovine serum (FBS; Gibco-BRL).
he 108 strain of BHV-1 was propagated in these cells.
lasmids
Plasmids pSLIAgD and pSLIAtgD were constructed by
loning the genes coding for gD and a truncated version
f gD (tgD) into pSL301 (Invitrogen, Carlsbad, CA) as
escribed previously (Tikoo et al., 1990; Braun et al.,
997). The truncated form of gD lacks the transmem-
rane anchor and cytoplasmic domain and is therefore
ecreted from transfected cells. The plasmids were am-
lified in transformed Escherichia coli (DH5aa strain)
nd purified using anion exchange resins (Qiagen,
hatsworth, CA). After the concentrations were deter-
ined, the plasmids were stored at 220°C. The A260/
80 ratios were typically 1.8 or higher. They were shown
o be free of endotoxins with the Limulus Amoebocyte
ysate Kit (Bio-Whittaker, Walkersville, MD).
uppositoriesEach suppository consisted of 2 g suppository base
Witepsol H-15” (Wiler Fine Chemicals Ltd., London, On-
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332 LOEHR ET AL.tario, Canada) containing triglycerides (,85%), diglycer-
ides (,15%), and monoglycerides (,1%), and 500 mg
plasmid (167 mg pSLIAgD and 333 mg pSLIAtgD) in 180
ml ddH2O. The suppository base was melted at 56°C,
and the plasmids in ddH2O were added and vortexed.
he resulting suspension was cooled while being vor-
exed and poured into molds shortly before hardening. To
ssess that the plasmids remained supercoiled, a sup-
ository was heated at 39°C and the DNA was collected
nd run on a 1% agarose gel, either directly or after
thanol precipitation.
mmunizations and challenge
BHV-1 seronegative heifers were randomly allocated
o two groups. Four animals received two suppositories
2, 8, and 3 weeks before challenge. The suppositories
ere manually applied into the distal part of the vagina of
he heifers. Seven animals remained in the control group
nd were housed under similar conditions in an adjoin-
ng pen to prevent nose-to-genital contact between the
roups. The control group was not vaccinated. Three
eeks after the last immunization, each animal was
xposed for 4 min to an aerosol of 107 PFU/ml of BHV-1
train 108, which was generated by a DeVilbis Nebulizer
odel 65 (DeVilbis, Barrie, ON). Following challenge, the
nimals were comingled. Body weights, rectal tempera-
ures, and clinical scores were determined on the day of
hallenge and for 10 days afterward.
ampling
Sera were collected at the time of each immunization
nd on the day of challenge. Nasal tampons were used
o obtain up to 5 ml of nasal fluid from all animals 6 days
efore challenge. Sera and nasal fluids were collected
gain on days 2, 4, 6, 8, 10, 13, and 17 postchallenge.
irus isolation
Nasal fluid was centrifuged at 1000 g for 20 min,
titrated in 10-fold dilutions in cold MEM, and 100 ml was
added to each of four wells of Nunc 96-well plates
(Gibco-BRL). Fifty microliters of freshly trypsinized MDBK
cells in MEM plus 5% FBS, with 300,000 cells/ml, were
added and incubated at 37°C. After 5 days the plates
were stained with crystal violet and virus titers were
determined and expressed as PFU/ml (van Drunen Littel-
van den Hurk et al., 1993).
Enzyme-linked immunosorbent assays
Polystyrene microtiter plates (Immulon 2, Dynatech
Laboratories, Gaithersburg, MD) were coated with 0.05
mg tgD per well (van Drunen Littel-van den Hurk et al.,
1993) and incubated with serially diluted bovine sera,
starting at 1:10, followed by threefold dilutions. Alkaline
phosphatase (AP)-conjugated goat anti-bovine IgG(Kirkegaard and Perry Laboratories, Gaithersburg, MD)
at a dilution of 1:10,000 was used to detect IgG, and
biotin-labeled goat anti-bovine IgA (VMDR, Pullman, WA)
at a dilution of 1:15,000, followed by streptavidin alkaline
phosphatase (Gibco-BRL) at a dilution of 1:3000, was
used to detect IgA. To detect secretory IgA, rabbit anti-
bovine sIgA (Nordic Immunological Laboratories, Tilburg,
the Netherlands), at a dilution of 1:2000, followed by
AP-labeled goat anti-rabbit IgG (Kirkegaard and Perry
Laboratories), at a dilution of 1:5000, were used. The
reactions were visualized with p-nitrophenyl phosphate
(Sigma Chemical Co., Oakville, ON).
Size-exclusion HPLC
Nasal fluids of vaccinated and control animals were
concentrated and buffer was added to a final concentra-
tion of 0.01 M Tris–HCl, 0.15 M NaCl, pH 7.4. The samples
were applied to a gel exclusion column (Keystone GFS
150, 300 3 8 mm, Keystone Scientific Inc., Bellefonte, PA).
Fractions of 0.5 ml each were collected and analyzed for
the presence of sIgA by ELISA. The retention time of the
fractions with sIgA was compared to the retention times
of the molecular weight markers catalase (232 kDa) and
aldolase (158 kDa).
Virus neutralization assays
The neutralization titers in the sera and nasal secre-
tions were determined as previously described (van
Drunen Littel-van den Hurk et al., 1990). The titers were
expressed as the highest dilution of antibody that caused
a 50% reduction of plaques relative to the virus control.
Statistical analyses
All data were analyzed with the aid of a statistical
software program (Systat 7.0, SPSS Inc., Chicago, IL).
ELISA data were transformed prior to performing the
analysis to normality by log transformation. Differences
between the groups were examined by performing two-
way ANOVA and Tukey HSD multiple comparison for
ELISA titers, virus neutralization titers, weights, and virus
shedding.
ACKNOWLEDGMENTS
The authors are grateful to the animal support staff at VIDO for care
and handling of the animals. We thank Brenda Karvonen and Laura
Latimer for excellent technical assistance, Dr. Baca-estrada for the
bovine sIgA-specific antibodies, and Dr. Attah-Poku for assistance with
the HPLC. Financial support was provided by grants from the Natural
Science and Engineering Research Council of Canada, Canadian In-
stitutes of Health Research, Alberta Beef Industry Development Fund,
Alberta Agricultural Research Institute, Beef Cattle Industry Develop-
ment Fund, Ontario Cattle Association, and Agricultural Development
Fund of Saskatchewan.
FF
G
G
G
H
I
K
K
K
L
L
L
M
M
O
S
S
S
T
V
V
W
X
Y
333SUPPOSITORY-MEDIATED DNA IMMUNIZATION OF CATTLEREFERENCES
Asakura, Y., Hinkula, J., Leandersson, A. C., Fukushima, J., Okuda, K.,
and Wahren, B. (1997). Induction of HIV-1 specific mucosal immune
responses by DNA vaccination. Scand. J. Immunol. 46, 326–330.
Babiuk, L. A., Babiuk, S., Loehr, B. I., and van Drunen Littel-van den
Hurk, S. (2000). Nucleic acid vaccines: Research tool or commercial
reality. Vet. Immunol. Immunopathol. 76, 1–23.
Babiuk, L. A., L’Italien, J., van Drunen Littel-van den Hurk, S., Zamb, T.,
Lawman, M. J. P., Hughes, G., and Gifford, G. A. (1987). Protection of
cattle from bovine herpesvirus type I (BHV-1) infection by immuniza-
tion with individual viral glycoproteins. Virology 159, 57–66.
Bagarazzi, M. L., Boyer, J. D., Javadian, M. A., Chattergoon, M., Dang, K.,
Kim, G., Shah, J., Wang, B., and Weiner, D. B. (1997). Safety and
immunogenicity of intramuscular and intravaginal delivery of HIV-1
DNA constructs to infant chimpanzees. J. Med. Primatol. 26, 27–33.
Barron, L. G., Uyechi, L. S., and Szoka F. C., Jr. (1999). Cationic lipids are
essential for gene delivery mediated by intravenous administration of
lipoplexes. Gene Ther. 6, 1179–1183.
Braun, R. P., Babiuk, L. A., Loehr, B. I., and van Drunen Littel-van den
Hurk, S. (1999). Particle-mediated DNA immunization of cattle con-
fers long-lasting immunity against bovine herpesvirus-1. Virology
265, 46–56.
Braun, R., Babiuk, L. A., and van Drunen Littel-van den Hurk, S. (1997).
Enhanced immune response to an intradermally delivered DNA vac-
cine expressing a secreted from of BHV-1 gD. Vaccine Res. 6,
151–164.
Chen, S. C., Jones, D. H., Fynan, E. F., Farrar, G. H., Clegg, J. C.,
Greenberg, H. B., and Herrmann, J. E. (1998). Protective immunity
induced by oral immunization with a rotavirus DNA vaccine encap-
sulated in microparticles. J. Virol. 72, 5757–5761.
Daheshia, M., Kuklin, N., Manickan, E., Chun, S., and Rouse, B. T. (1998).
Immune induction and modulation by topical ocular administration of
plasmid DNA encoding antigens and cytokines. Vaccine 16, 1103–
1110.
Donnelly, J. J., Ulmer, J. B., and Liu, M. A. (1997). DNA vaccines. Annu.
Rev. Immunol. 15, 617–648.
elgner, P. L., Tsai, Y. J., Sukhu, L., Wheeler, C. J., Manthorpe, M.,
Marshall, J., and Cheng, S. H. (1995). Improved cationic lipid formu-
lations for in vivo gene therapy. Rev. Ann. NY Acad. Sci. 772, 126–139.
ynan, E. F., Webster, R. G., Fuller, D. H., Haynes, J. R., Santoro, J. C., and
Robinson, H. L. (1993). DNA vaccines: Protective immunizations by
parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad.
Sci. USA 90, 11478–11482.
allichan, W. S., and Rosenthal, K. L. (1995). Specific secretory immune
responses in the female genital tract following intranasal immuniza-
tion with a recombinant adenovirus expressing glycoprotein B of
herpes simplex virus. Vaccine 13, 1589–1595.
erdts, V., Babiuk, L. A., van Drunen Littel-van den Hurk, S., and Griebel,
P. J. (2000). Fetal immunization by a DNA vaccine delivered in the
amniotic fluid. Nat. Med. 6, 929–939.
regoriadis, G., Saffie, R., and de Souza, J. B. (1997). Liposome-medi-
ated DNA vaccination. FEBS Lett. 402, 107–110.
aneberg, B., Kendall, D., Amerongen, H. M., Apter, F. M., Kraehenbuhl,
J. P., and Neutra, M. R. (1994). Induction of specific immunoglobulin
A in the small intestine, colon-rectum, and vagina measured by a
new method for collection of secretions from local mucosal surfaces.
Infect. Immunol. 62, 15–23.
shii, N., Fukushima, J., Kaneko, T., Okada, E., Tani, K., Tanaka, S. I.,
Hamajima, K., Xin, K. Q., Kawamoto, S., Koff, W., Nishioka, K., Yasuda,
T., and Okuda, K. (1997). Cationic liposomes are a strong adjuvant for
a DNA vaccine of human immunodeficiency virus type 1. AIDS Res.
Hum. Retroviruses 13, 1421–1428.lavinskis, L. S., Barnfield, C., Gao, L., and Parker, S. (1999). Intranasal
immunization with plasmid DNA-lipid complexes elicits mucosalimmunity in the female genital and rectal tracts. J. Immunol. 162,
254–262.
lavinskis, L. S., Gao, L., Barnfield, C., Lehner, T., and Parker, S. (1997).
Mucosal immunization with DNA-liposome complexes. Vaccine 15,
818–820.
uklin, N., Daheshia, M., Karem, K., Manickan, E., and Rouse, B. T.
(1997). Induction of mucosal immunity against herpes simplex virus
by plasmid DNA immunization. J. Virol. 71, 3138–3145.
oehr, B. I., Babiuk, L. A., and van Drunen Littel-van den Hurk, S. (2000).
Gene gun mediated DNA immunization primes the development of
mucosal immunity against bovine herpesvirus-1 in cattle. J. Virol. 74,
6077–6086.
undholm, P., Asakura, Y., Hinkula, J., Lucht, E., and Wahren, B. (1999).
Induction of mucosal IgA by a novel jet delivery technique for HIV-1
DNA. Vaccine 17, 2036–2042.
unn, D. P., Soboll, G., Schram, B. R., Quass, J., McGregor, M. W., Drape,
R. J., Macklin, M. D., McCabe, D. E., Swain, W. F., and Olsen, C. W.
(1999). Antibody responses to DNA vaccination of horses using the
influenza virus hemagglutinin gene. Vaccine 17, 2245–2258.
acklin, M. D., McCabe, D., McGregor, M. W., Neumann, V., Meyer, T.,
Callan, R., Hinshaw, V. S., and Swain, W. F. (1998). Immunization of
pigs with a particle-mediated DNA vaccine to influenza A virus
protects against challenge with homologous virus. J. Virol. 72, 1491–
1496.
cCluskie, M. J., Chu, Y., Xia, J. L., Jessee, J., Gebyehu, G., and Davis,
H. L. (1998). Direct gene transfer to the respiratory tract of mice with
pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug
Dev. 8, 401–414.
gra, P. L., Mestecky, J., Lamm, M. E., Strober, W., McGhee, J. R., and
Bienenstock, J. (1994). “Handbook of Mucosal Immunology.” pp.
1–766. Academic Press, San Diego, CA.
agodira, S., Buzoni-Gatel, D., Iochmann, S., Naciri, M., and Bout, D.
(1999). Protection of kids against Cryptosporidium parvum infection
after immunization of dams with CP15-DNA. Vaccine 17, 2346–2355.
ha, Z., Vincent, M. J., and Compans, R. W. (1999). Enhancement of
mucosal immune responses to the influenza virus HA protein by
alternative approaches to DNA immunization. Immunobiology 200,
21–30.
ingh, M., Briones, M., Ott, G., and O’Hagan, D. (2000). Cationic micro-
particles: A potent delivery system for DNA vaccines. Proc. Natl.
Acad. Sci. USA 97, 811–816.
ikoo, S. K., Fitzpatrick, D., Babiuk, L. A., and Zamb, T. J. (1990).
Molecular cloning, sequencing and expression of functional bovine
herpesvirus-1 glycoprotein gIV in transfected bovine cells. J. Virol. 64,
5132–5142.
an Drunen Littel-van den Hurk, S., Gifford, G. A., and Babiuk, L. A.
(1990). Epitope specificity of the protective immune response in-
duced by individual bovine herpesvirus-1 glycoproteins. Vaccine 8,
358–367.
an Drunen Littel-van den Hurk, S., Parker, M. D., Massie, B., van den
Hurk, J. V., Harland, R., Babiuk, L. A., and Zamb, T. J. (1993). Protection
of cattle from BHV-1 infection by immunization with recombinant
glycoprotein gIV. Vaccine 11, 25–35.
ang, B., Dang, K., Agadjanyan, M. G., Srikantan, V., Li, F., Ugen, K. E.,
Boyer, J., Merva, M., Williams, W. V., and Weiner, D. B. (1997). Mucosal
immunization with a DNA vaccine induces immune responses
against HIV-1 at a mucosal site. Vaccine 15, 821–825.
in, K. Q., Hamajima, K., Sasaki, S., Honsho, A., Tsuji, T., Ishii, N., Cao,
X. R., Lu, Y., Fukushima, J., Shapshak, P., Kawamoto, S., and Okuda,
K. (1998). Intranasal administration of human immunodeficiency virus
type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid
enhances cell-mediated immunity against HIV-1. Immunology 94,
438–444.
ates, W. D. G. (1982). A review of infectious bovine rhinotracheitis,
shipping fever pneumonia and viral bacterial synergism in respira-
tory disease of cattle. Can. J. Comp. Med. 46, 225–263.
